Sensei Biotherapeutics (SNSE) 10-Q2023 Q3 Quarterly report

Filed: 7 Nov 23, 4:40pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abolishing, acneiform, agonism, agonist, arm, backbone, bivalent, bronchial, bypassing, Cluster, compartment, concordance, confirmed, consecutive, customary, delist, delisting, Differentiation, distinct, East, engineered, Fc, format, Immunotherapy, infiltrating, inflammatory, letter, low, mediated, Middle, molecule, monovalent, myeloid, notable, notifying, oAs, obstruction, oFollowing, oWhile, paragraph, pathway, pH, poster, prototype, provisionally, receptor, regain, signaling, SITC, Society, stymied, toxicity, unanimously

Removed: highest, poor, unleash

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SNSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF

PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, Inc. (the “Company”), and Erin Colgan, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

(1)

The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

(2)

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 7th day of November 2023.


/s/ John Celebi		/s/ Erin Colgan
John Celebi		Erin Colgan
President and Chief Executive Officer (Principal Executive Officer)		Chief Financial Officer (Principal Financial Officer)

* This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.